Hôpital Louis Pradel
Lyon, 69677, France
Location status: Recruiting
Location contact
Raphaële Guelminger, CRA
CONTACT
Vincent Cottin, MD
CONTACT
NCT Number: NCT01484236
RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis.
Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Lyon, 69677, France
Location status: Recruiting
Raphaële Guelminger, CRA
CONTACT
Vincent Cottin, MD
CONTACT
Lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. Few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression.
Several sources of information will be used in order to increase completeness. The registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Competence Centers for rare lung diseases in France.
Data will be collected by a research assistant, and the study will be coordinated by the Pole IMER - Department of Public health and Epidemiology of HCL (Lyon Hospitals).
This study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. This study will provide the first detailed epidemiological information on Lymphangioleiomyomatosis, will assess the management of this rare disease within the French National Plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 4 years
Determine incidence and prevalence of lymphangioleiomyomatosis.
Time frame: 4 years
Estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Centers of excellence for rare lung diseases in France (coverage rate of centers)
Time frame: 4 years
Determine the frequency of the various forms with mild to moderate or severe, and rapid or slow evolution.
Time frame: 4 years
Determine applicability of diagnostic criteria proposed in 2009
Contact information is provided by the study sponsor or research team.
Vincent COTTIN
Other
Acronym: RE-LAM-CE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05676099
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT00001465
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT01799538
Hemic and Lymphatic Diseases, Immune System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06160310
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cincinnati, Ohio, United States
View Trial Details